Bayer to work with Schrdinger on a molecule design software, which will be integrated into the latters LiveDesign, a digital drug design platform. Under the five-year collaboration agreement, Bayer and Schrdinger aim to develop a virtual platform, which will be able to enumerate, screen and design synthetically feasible compounds potentially leading to the development and optimization of new therapeutic candidates. The collaborative work will be based on Schrdingers molecular design technology and machine learning capabilities, while Bayer, on its side, will provide the in silico models that are able to predict the absorption, distribution, metabolism, excretion, toxicity and chemical synthesizability of the compounds. The software will be built leveraging Schrdingers LiveDesign platform, a digital platform enabling the in silico design of therapeutic candidates.